

THE GENERAL ASSEMBLY OF PENNSYLVANIA

HOUSE BILL

No. 1651 Session of
2011

INTRODUCED BY DiGIROLAMO, COHEN, BAKER, BISHOP, BOYD, BRENNAN,
R. BROWN, CALTAGIRONE, CLYMER, DAVIS, J. EVANS, GEIST,
GINGRICH, GROVE, HAHN, HARHAI, HARKINS, HEFFLEY, HELM,
HENNESSEY, HESS, HORNAMAN, KILLION, KOTIK, KULA, MANN,
MICOZZIE, MURPHY, MURT, MYERS, PYLE, QUINN, REICHLEY, SAYLOR,
SCAVELLO, CULVER, K. SMITH, TAYLOR, THOMAS AND VULAKOVICH,
JUNE 8, 2011

REFERRED TO COMMITTEE ON HUMAN SERVICES, JUNE 8, 2011

AN ACT

1 Amending Title 44 (Law and Justice) of the Pennsylvania
2 Consolidated Statutes, establishing the Pharmaceutical
3 Accountability Monitoring System; and imposing penalties.

4 The General Assembly of the Commonwealth of Pennsylvania
5 hereby enacts as follows:

6 Section 1. Title 44 of the Pennsylvania Consolidated
7 Statutes is amended by adding a chapter to read:

8 CHAPTER 27

9 PHARMACEUTICAL ACCOUNTABILITY MONITORING SYSTEM

10 Sec.

11 2701. Short title of chapter.

12 2702. Scope of chapter.

13 2703. Definitions.

14 2704. Establishment of Pharmaceutical Accountability Monitoring
15 System.

16 2705. Requirements for Pharmaceutical Accountability Monitoring

1 System.
2 2706. Access to prescription information.
3 2707. Unlawful acts and penalties.
4 2708. Education and treatment.
5 2709. Immunity.
6 2710. Additional provisions.
7 2711. Use of money collected.
8 2712. Rules and regulations.
9 2713. Evaluation, data analysis and reporting.
10 2714. Severability.
11 § 2701. Short title of chapter.

12 This chapter shall be known and may be cited as the
13 Pharmaceutical Accountability Monitoring System Act.

14 § 2702. Scope of chapter.

15 This chapter is intended to improve the Commonwealth's
16 ability to enable informed and responsible prescribing and
17 dispensing of controlled substances and to reduce diversion and
18 misuse of such drugs in an efficient and cost-effective manner
19 that will not impede the appropriate medical utilization of
20 licit controlled substances.

21 § 2703. Definitions.

22 The following words and phrases when used in this chapter
23 shall have the meanings given to them in this section unless the
24 context clearly indicates otherwise:

25 "Alcohol and other drug addiction treatment program." Any
26 facility or treatment program that is licensed, certified or
27 approved by the Commonwealth to provide alcohol and other drug
28 addiction treatment on a hospital, nonhospital, residential or
29 outpatient basis.

30 "Controlled substance." A drug, substance or immediate

precursor included in Schedule II, III, IV or V of the act of
April 14, 1972 (P.L.233, No.64), known as The Controlled
Substance, Drug, Device and Cosmetic Act, or the Controlled
Substances Act (Public Law 91-513, 84 Stat. 1236).

"Database." The Pharmaceutical Accountability Monitoring
System established in section 2704 (relating to establishment of
Pharmaceutical Accountability Monitoring System).

"Department." The Department of Drug and Alcohol Programs.

"Dispenser." A provider who dispenses a scheduled drug to a
patient in this Commonwealth but does not include any of the
following:

(1) A licensed health care facility or long-term care
pharmacy that distributes such substances for the purpose of
inpatient hospital or long-term care facility administration.

(2) A practitioner or other authorized person who
administers such a substance.

(3) A wholesale distributor of a scheduled drug.

(4) A hospice care provider.

"Licensed health care facility." A health care facility that
is licensed under Article X of the act of June 13, 1967 (P.L.
31, No.21), known as the Public Welfare Code, or the act of July
19, 1979 (P.L.130, No.48), known as the Health Care Facilities
Act.

"PAMS." The Pharmaceutical Accountability Monitoring System
established in section 2704.

"Patient." The person who has lawfully obtained and who
possesses any scheduled drug for the person's own use.

"Practitioner." The term shall mean:

(1) a physician, osteopath, dentist, veterinarian,
pharmacist, podiatrist, nurse, scientific investigator or

1 other person licensed, registered or otherwise permitted to
2 distribute, dispense, conduct research with respect to or to
3 administer a controlled substance, other drug or device in
4 the course of professional practice or research in this
5 Commonwealth; or

6 (2) a pharmacy, hospital, clinic or other institution
7 licensed, registered or otherwise permitted to distribute,
8 dispense, conduct research with respect to or to administer a
9 controlled substance, other drug or device in the course of
10 professional practice or research in this Commonwealth.

11 § 2704. Establishment of Pharmaceutical Accountability
12 Monitoring System.

13 (a) General rule.--The department shall establish and
14 maintain an electronic system for monitoring all scheduled drugs
15 that are dispensed within this Commonwealth by all professionals
16 licensed to prescribe or dispense such substances in this
17 Commonwealth, including, but not limited to, a practitioner or
18 pharmacist or dispensed to an address within this Commonwealth
19 by a pharmacy that has obtained a license, permit or other
20 authorization to operate by the Pennsylvania Board of Pharmacy.

21 (b) Duties of department.--The department shall administer
22 PAMS.

23 (c) Purpose.--The purpose of PAMS is to contain data as
24 described in this section regarding every prescription for a
25 controlled substance dispensed in this Commonwealth to any
26 person other than an inpatient in a licensed health care
27 facility or by a hospice care provider.

28 (d) Data compliance.--Data required by this section shall be
29 submitted in compliance with this section to the department by
30 the pharmacy or other dispensing entity.

1 (e) Data input.--A dispenser shall input data as required by
2 the department.

3 (f) Queries.--A practitioner may query such data.

4 (g) Registration.--Each dispenser and practitioner licensed
5 to practice in this Commonwealth shall register with and
6 establish a user name and personal identification number that
7 permits access to the secure website housing PAMS established by
8 this act.

9 (h) Dispenser access.--Each dispenser required to report
10 electronically pursuant to this act shall have online access to
11 PAMS at all times when the dispenser provides pharmaceutical
12 care to a patient potentially receiving a controlled substance.

13 § 2705. Requirements for Pharmaceutical Accountability
14 Monitoring System.

15 (a) Submission.--The dispenser shall, regarding each
16 controlled substance dispensed, submit by electronic means to
17 the department the following information by transmission
18 methods, protocols and in a format established by the
19 department:

20 (1) Full name of the prescribing practitioner.

21 (2) Prescriber Drug Enforcement Agency (DEA)
22 registration number.

23 (3) Date the prescription was written.

24 (4) Date the prescription was dispensed.

25 (5) Patient information of the person for whom the
26 prescription was written and dispensed, including full name,
27 date of birth, gender and address.

28 (6) Positive identification of the person receiving the
29 prescription, including the type of identification.

30 (7) Name of the controlled substance.

1 (8) Quantity of the controlled substance prescribed.

2 (9) Strength of the controlled substance.

3 (10) Quantity of the controlled substance dispensed.

4 (11) Dosage quantity and frequency prescribed.

5 (12) Name of the pharmacy or other entity dispensing the
6 controlled substance.

7 (13) Name of the pharmacist dispensing the controlled
8 substance.

9 (14) Dispensing entity's DEA registration number and
10 NPI.

11 (15) Source of payment for the prescription.

12 (16) Other relevant information as established by
13 department regulations.

14 (b) Frequency.--Each dispenser shall submit the information
15 required by this act as frequently as specified by the
16 department, but not later than two days after the dispensing of
17 a controlled substance monitored by PAMS. The department shall
18 implement a real-time reporting requirement as expeditiously as
19 possible.

20 (c) Maintenance.--The department shall maintain PAMS in an
21 electronic file or by other means established by the department
22 to facilitate use of the database for identification of:

23 (1) Prescribing and dispensing practices and patterns
24 for controlled substances.

25 (2) An individual patient's patterns of obtaining
26 controlled substances from licensed practitioners and who
27 subsequently obtain dispensed controlled substances from a
28 drug outlet in quantities or with a frequency inconsistent
29 with generally recognized standards of dosage for that
30 controlled substance.

1 (3) Individuals presenting forged or otherwise false or
2 altered prescriptions for controlled substances to a
3 pharmacy.

4 (d) Recordkeeping.--The department shall maintain a record
5 of PAMS queries for reference, including:

6 (1) Identification of each person who requests or
7 receives information from PAMS.

8 (2) The information provided to each person.

9 (3) The date and time the information is requested or
10 provided.

11 § 2706. Access to prescription information.

12 (a) General rule.--Except as set forth in subsection (c),
13 prescription information submitted to the department shall be
14 confidential and not subject to disclosure under the act of
15 February 14, 2008 (P.L.6, No.3), known as the Right-to-Know Law.

16 (b) Privacy procedures.--The department shall maintain
17 procedures to ensure that the privacy and confidentiality of
18 patients and patient information collected, recorded,
19 transmitted and maintained is not disclosed to persons except
20 those enumerated in subsection (c).

21 (c) Limited availability.--The manager of PAMS shall make
22 information in PAMS available only to the following persons and
23 in accordance with the limitations stated in the department
24 regulations:

25 (1) Personnel of the department specifically assigned to
26 conduct investigations related to controlled substances laws
27 under the jurisdiction of the department.

28 (2) Authorized department personnel engaged in analysis
29 of controlled substance prescription information as a part of
30 the assigned duties and responsibilities of their employment.

1 (3) Qualified personnel for the purpose of bona fide
2 research or education. Data elements that would reasonably
3 identify a specific recipient, prescriber or dispenser shall
4 be deleted or redacted from such information prior to
5 disclosure. Release of the information shall only be made
6 pursuant to a written agreement between such qualified
7 personnel and the department in order to ensure compliance
8 with this chapter.

9 (4) A licensed practitioner, or a representative
10 employed by the practitioner, designated by the practitioner
11 pursuant to criteria established by the department, having
12 authority to prescribe controlled substances, to the extent
13 of one of the following:

14 (i) The information relates to a current patient of
15 the practitioner to whom the practitioner is prescribing
16 or considering prescribing any controlled substance.

17 (ii) The information relates specifically to an
18 individual who has access to the practitioner's DEA
19 number, and the practitioner suspects that the individual
20 may use the practitioner's DEA identification number to
21 fraudulently acquire or prescribe controlled substances.

22 (iii) The information relates to the practitioner's
23 own prescribing practices, except when specifically
24 prohibited by department regulations.

25 (5) A licensed pharmacist, or a designee employed by the
26 pharmacist, designated by the pharmacist pursuant to criteria
27 established by the department, having authority to dispense
28 controlled substances to the extent the information relates
29 specifically to a current patient to whom that pharmacist is
30 dispensing or considering dispensing any controlled

1 substance.

2 (6) Federal or State law enforcement authorities engaged
3 in the administration, investigation or enforcement of the
4 laws governing controlled substances and who are involved in
5 one of the following:

6 (i) A bona fide specific drug-related investigation
7 involving a designated person.

8 (ii) Investigating insurance fraud, Medicaid fraud
9 or Medicare fraud.

10 (7) A designated representative from the Commonwealth or
11 out-of-State agency or board responsible for licensing or
12 certifying prescribers or dispensers who is involved in a
13 bona fide investigation of a prescriber or dispenser whose
14 professional practice was or is regulated by that agency or
15 board.

16 (8) A medical examiner or county coroner for the purpose
17 of investigating the death of an individual.

18 (9) A designated prescription monitoring official of a
19 state with which this Commonwealth has an interoperability
20 agreement may access prescription monitoring information in
21 accordance with procedures adopted by the department.

22 (10) An individual who is the recipient of a controlled
23 substance prescription entered into PAMS upon providing
24 evidence satisfactory to the PAMS manager that the individual
25 requesting the information is in fact the person about whom
26 the data entry was made.

27 (11) A judicial authority under grand jury subpoena or
28 court order or equivalent judicial process for investigation
29 of a criminal violation of law governing controlled
30 substances may access prescription monitoring information.

1 § 2707. Unlawful acts and penalties.

2 (a) Knowing and intentional release.--Any person who
3 knowingly and intentionally releases any information in PAMS in
4 violation of the limitations under section 2706(c) (relating to
5 access to prescription information) commits a felony of the
6 third degree.

7 (b) Misrepresentation or fraud.--Any person who obtains or
8 attempts to obtain information from PAMS by misrepresentation or
9 fraud commits a felony of the third degree.

10 (c) Unauthorized purpose.--Any person who obtains or
11 attempts to obtain information from PAMS for a purpose other
12 than a purpose authorized by this section or by department
13 regulations commits a felony of the third degree.

14 (d) Other person.--A person may not knowingly and
15 intentionally use, release, publish or otherwise make available
16 to any other person or entity any information obtained from PAMS
17 for any purpose other than those specified in section 2706(c).
18 Each separate violation of this subsection is a felony of the
19 third degree and is subject to a civil penalty not to exceed
20 \$5,000.

21 (e) Civil violation.--The procedure for determining a civil
22 violation of this subsection shall be in accordance with
23 department regulations. Civil penalties assessed under this
24 subsection shall be deposited in the General Fund, appropriated
25 to the department and dedicated to the controlled substance PAMS
26 operations.

27 (f) Failure to submit.--The failure of a dispenser to submit
28 information to PAMS as required under this section, after the
29 department has submitted a specific written request for the
30 information or when the department determines the individual has

a demonstrable pattern of knowing that failure to submit the information as required, is grounds for the pharmacy board to take the following action in accordance with the act of September 27, 1961 (P.L.1700, No.699), known as the Pharmacy Act.

(1) Refuse to issue a license to the individual.

(2) Refuse to renew the individual's license.

(3) Revoke, suspend, restrict or place on probation the license.

(4) Issue a public or private reprimand to the individual.

(5) Issue a cease and desist order.

(6) Impose a civil penalty of not more than \$1,000 for each dispensed prescription for which the required information was not submitted.

(g) A person authorized to have prescription monitoring information under this act who knowingly uses such information in violation of this act shall, upon conviction, be fined not less than \$5,000, be sentenced to imprisonment of not more than 90 days, or both, for each offense.

§ 2708. Education and treatment.

(a) General rule.--The department shall:

(1) assist the appropriate agency, board or association for each category of authorized user in this act to incorporate the appropriate information regarding PAMS into the training, education or instruction provided to each category of authorized user;

(2) assist the State or regional chapter of the American Society of Addiction Medicine, or comparable association in this Commonwealth, and the medical society to develop a

1 continuing education course for health care professionals on
2 prescribing practices, pharmacology and identification,
3 referral and treatment of patients addicted to or abusing
4 controlled substances monitored by PAMS; and

5 (3) implement, or assist other appropriate agencies to
6 implement, an educational program to inform the public about
7 the use, diversion and abuse of, addiction to and treatment
8 for the addiction to the controlled substances monitored by
9 PAMS.

10 (b) Referral.--The department shall refer prescribers and
11 dispensers it has reason to believe may be impaired to the
12 appropriate professional licensing or certification agency, and
13 to the appropriate impaired professionals associations, to
14 provide intervention, assessment and referral to alcohol and
15 other drug addiction treatment programs, and ongoing monitoring
16 and follow-up.

17 (c) Identification.--The department shall work with the
18 appropriate alcohol and other drug addiction treatment
19 professionals to provide that patients identified through PAMS
20 as potentially addicted to a controlled substance are assessed
21 and referred to alcohol and other drug addiction treatment
22 programs.

23 § 2709. Immunity.

24 An individual who has submitted information to PAMS in
25 accordance with this section may not be held civilly liable for
26 having submitted the information.

27 § 2710. Additional provisions.

28 (a) Funding.--A practitioner or a pharmacist shall not be
29 required to pay a fee or tax specifically dedicated to
30 establishment, operation or maintenance of the system.

1 (b) Costs.--All costs associated with recording and
2 submitting data as required in this section shall be assumed by
3 the submitting pharmacy.

4 (c) Use of data.--Except as provided in subsection (d), data
5 provided to, maintained in or accessed from PAMS that may be
6 identified to, or with, a particular person is not subject to
7 discovery, subpoena or similar compulsory process in any civil,
8 judicial, administrative or legislative proceeding, nor shall
9 any individual or organization with lawful access to the data be
10 compelled to testify with regard to the data.

11 (d) Exceptions.--The restrictions in subsection (c) do not
12 apply to:

13 (1) A criminal proceeding.

14 (2) A civil, judicial or administrative action brought
15 to enforce the provisions of this section.

16 § 2711. Use of money collected.

17 (a) General rule.--The department may use the moneys
18 deposited in the General Fund and appropriated to the department
19 for the following purposes:

20 (1) Maintenance and replacement of PAMS equipment,
21 including hardware and software.

22 (2) Training of staff.

23 (3) Pursuit of grants and matching funds.

24 (b) Collections.--The department may collect any penalty
25 imposed under section 2707 (relating to unlawful acts and
26 penalties) and which is not paid by bringing an action in the
27 court of common pleas of the county in which the person owing
28 the debt resides or in the county where the department is
29 located.

30 (c) Legal assistance.--The department may seek legal

1 assistance from the Attorney General or the county or district
2 attorney of the county in which the action is brought to collect
3 the fine.

4 (d) Attorney fees and costs.--The court shall award
5 reasonable attorney fees and costs to the department for
6 successful collection actions under section 2707.

7 § 2712. Rules and regulations.

8 The department shall promulgate rules and regulations setting
9 forth the procedures and methods for implementing this chapter.
10 At a minimum, the rules and regulations shall include the
11 following:

12 (1) Effectively enforce the limitations on access to
13 PAMS prescribed in section 2706 (relating to access to
14 prescription information).

15 (2) Establish standards and procedures to ensure
16 accurate identification of individuals requesting information
17 or receiving information from PAMS.

18 § 2713. Evaluation, data analysis and reporting.

19 (a) General rule.--The department shall design and implement
20 an evaluation component to identify:

21 (1) cost benefits of PAMS;

22 (2) the impact on efforts to reduce misuse, abuse,
23 overdose and diversion of, or addiction to, controlled
24 substances;

25 (3) the impact on prescribing practices for controlled
26 substances;

27 (4) the number of patients identified through PAMS as
28 potentially addicted to a controlled substance that were
29 assessed for alcohol and other drug addictions;

30 (5) the number of patients in paragraph (4) that

1 received alcohol and other drug addiction treatment and the
2 names of the licensed, certified or approved alcohol and
3 other drug addiction treatment facilities in which the
4 patients were treated;

5 (6) the progress made in implementing real-time
6 reporting; and

7 (7) other information relevant to policy, research and
8 education involving controlled substances and drugs of
9 concern monitored by PAMS.

10 (b) Annual report.--The department shall annually report the
11 information specified in subsection (a) to the Public Health and
12 Welfare Committee of the Senate, the Human Services Committee of
13 the House of Representatives, the United States Department of
14 Justice, the Substance Abuse and Mental Health Services
15 Administration of the Office of National Drug Control Policy and
16 members of Pennsylvania's United States Congressional
17 delegation. Additionally, the department shall make the annual
18 report available to the public on its publicly accessible
19 Internet website.

20 § 2714. Severability.

21 The provisions of this act are severable. If any provision of
22 this act or its application to any person or circumstance is
23 held invalid, the invalidity shall not affect other provisions
24 or applications of this act which can be given effect without
25 the invalid provision or application.

26 Section 2. This act shall take effect in 60 days.